AdvanCell
Develops lead-212 targeted alpha therapies to treat cancer
$315MSeries D
Role not disclosedLoading investors…
Activity from announced rounds
Develops lead-212 targeted alpha therapies to treat cancer
Developing transformative, best-in-class neuropsychiatric therapies
Develops precision immunoregulatory medicines based on tissue Treg biology
Provides healthcare financing and payments solutions
Pitching SV Health Investors? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room